IP Library › Patent Application 11988991
Patent Application
App. No. 11/988,991

Use of soluble guanylate cyclase activators for the treatment of Raynaud's Phenomenon

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/988,991
Abstract

The present invention relates to a method for prevention or treatment of primary and secondary Raynaud's phenomenon comprising administration of an effective amount of a compound selected from compounds of formulae I-IV, and to pharmaceutical compositions containing these compounds.

Claims (6)

1 . A method for prevention or treatment of primary and secondary Raynaud's phenomenon comprising administering an effective amount of a compound selected from compounds of the formulae (I-VI)

or a salt, hydrate, or hydrate of a salt thereof.

2 . The method as claimed in claim 1 , in which the compound is administered as an oral dosage form.

3 . The method as claimed in claim 1 , in which the compound is given intravenously.

4 . The method as claimed in claim 1 , in which the compound is preventive.

5 . A pharmaceutical composition for treating primary and secondary Raynaud's phenomenon, which comprises at least one substance as described in claim 1 .

Assignments (3)
MERGER Recorded Feb 18, 2011
From: BAYER HEALTHCARE AG
To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 025837/0666 →
MERGER Recorded Jan 6, 2010
From: BAYER HEALTHCARE AG
To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 023738/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2009
From: KRAHN, THOMAS; STASCH, JOHANNES-PETER; WEIMANN, GERRIT; THIELEMANN, WOLFGANG
To: BAYER HEALTHCARE AG
Reel/Frame 022952/0913 →